Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2006 2
2007 1
2008 3
2009 3
2010 1
2011 1
2012 2
2014 1
2016 1
2017 1
2018 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
Cheng JWM, Badreldin HA, Patel DK, Bhatt SH. Cheng JWM, et al. Curr Med Res Opin. 2017 Jun;33(6):985-992. doi: 10.1080/03007995.2017.1284052. Epub 2017 Feb 15. Curr Med Res Opin. 2017. PMID: 28097882 Review.
INTRODUCTION: This article reviews evidence of the benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008. STUDY SELECTION: Peer-reviewed articles were identified from MEDLINE and Current Content …
INTRODUCTION: This article reviews evidence of the benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a f …
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Raschi E, Poluzzi E, Koci A, Antonazzo IC, Marchesini G, De Ponti F. Raschi E, et al. Nutr Metab Cardiovasc Dis. 2016 May;26(5):380-6. doi: 10.1016/j.numecd.2016.02.006. Epub 2016 Feb 19. Nutr Metab Cardiovasc Dis. 2016. PMID: 27067162
BACKGROUND AND AIMS: We tested the possible association between dipeptidyl peptidase-4 inhibitors (DPP-4-I) use and heart failure (HF) occurrence by assessing the publicly available US-FDA Adverse Event Reporting System (FAERS). METHODS: FAERS data rep …
BACKGROUND AND AIMS: We tested the possible association between dipeptidyl peptidase-4 inhibitors (DPP-4-I) use and heart failure …
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Wallach JD, et al. BMJ. 2020 Feb 5;368:l7078. doi: 10.1136/bmj.l7078. BMJ. 2020. PMID: 32024657 Free PMC article.
The odds ratios for myocardial infarction, heart failure, cardiovascular related death, and non-cardiovascular related death were 1.17 (0.92 to 1.51), 1.54 (1.14 to 2.09), 1.15 (0.55 to 2.41), and 1.18 (0.60 to 2.30), respectively. ...CONCLUSIONS: The …
The odds ratios for myocardial infarction, heart failure, cardiovascular related death, and non-cardiovascular r …
After avandia: the use of antidiabetic drugs in patients with heart failure.
Khalaf KI, Taegtmeyer H. Khalaf KI, et al. Tex Heart Inst J. 2012;39(2):174-8. Tex Heart Inst J. 2012. PMID: 22740727 Free PMC article. Review.
Managing diabetes mellitus is an ongoing concern, especially in the presence of heart failure. Recent reports have drawn attention to adverse cardiovascular events associated with the use of thiazolidinediones, including rosiglitazone (Avandia). …
Managing diabetes mellitus is an ongoing concern, especially in the presence of heart failure. Recent reports have drawn atten …
[Cardiovascular effects of rosiglitazone].
Le Feuvre C. Le Feuvre C. Presse Med. 2004 Jun 19;33(11):735-45. doi: 10.1016/s0755-4982(04)98730-1. Presse Med. 2004. PMID: 15257231 Review. French.
Their side effects, generally minor or mild, are also well known. The problem of cardiovascular adverse events, although of a low incidence, should be known and recognized, notably fluid retention (and oedema) and risk of heart failure, more frequent i …
Their side effects, generally minor or mild, are also well known. The problem of cardiovascular adverse events, although of a …
[Heart, diabetes and glitazones].
Le Feuvre C. Le Feuvre C. Ann Endocrinol (Paris). 2004 Feb;65(1 Suppl):S26-35. doi: 10.1016/s0003-4266(04)95998-7. Ann Endocrinol (Paris). 2004. PMID: 15163921 Review. French.
Beneficial metabolic effects of rosiglitazone are now well established and its adverse events, generally minor or mild well known too. Following a brief review of these metabolic effects and main adverse events, we mainly describe fluid retention (and edema) …
Beneficial metabolic effects of rosiglitazone are now well established and its adverse events, generally minor or mild well kn …
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK. Habib ZA, et al. Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):437-47. doi: 10.1002/pds.1722. Pharmacoepidemiol Drug Saf. 2009. PMID: 19235778 Free PMC article.
The primary outcome was fatal and non-fatal acute myocardial infarction (AMI). Secondary outcomes included hospitalizations for congestive heart failure (CHF), fatal, and non-fatal cerebrovascular accidents (CVA) and transient ischemic attacks (TIA), combined corona …
The primary outcome was fatal and non-fatal acute myocardial infarction (AMI). Secondary outcomes included hospitalizations for congestive …
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors.
Schernthaner G. Schernthaner G. Int J Clin Pract. 2009 Jun;63(6):912-29. doi: 10.1111/j.1742-1241.2009.02025.x. Int J Clin Pract. 2009. PMID: 19490202 Review.
Limited data suggest that thiazolidinediones might also improve the circulating levels and functional activity of angiogenic endothelial progenitor cells, which independently predict the incidence of cardiovascular events and death. It should be noted that the US Fo …
Limited data suggest that thiazolidinediones might also improve the circulating levels and functional activity of angiogenic endothelial pro …
[Treatment of heart failure in diabetic patients].
Hradec J. Hradec J. Vnitr Lek. 2014 Apr;60(4):310-5. Vnitr Lek. 2014. PMID: 24985990 Review. Czech.
Heart failure occurs in diabetic patients and vice versa, among patients with heart failure is high prevalence of diabetes mellitus. Treatment of heart failure in diabetics is not substantially different from the treatment of heart …
Heart failure occurs in diabetic patients and vice versa, among patients with heart failure is high prevalence o …
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
Erdmann E, Spanheimer R, Charbonnel B; PROactive Study Investigators. Erdmann E, et al. J Diabetes. 2010 Sep;2(3):212-20. doi: 10.1111/j.1753-0407.2010.00082.x. J Diabetes. 2010. PMID: 20923486 Free article. Clinical Trial.
Patients received pioglitazone or placebo in addition to their baseline glucose-lowering and cardiovascular medications. The effect of pioglitazone on composite endpoints was evaluated, including all-cause death, myocardial infarction (MI), and stroke, as well as safety …
Patients received pioglitazone or placebo in addition to their baseline glucose-lowering and cardiovascular medications. The effect o …
20 results